is recognised by all experienced surgeons and interventional cardiologists; accurate evaluation of not only the dysfunctional valve, but also the subvalvular apparatus and commissural calcifications, impacts the outcomes of both surgical and percutaneous procedures.
The absence of commissural fusion or the presence of severe or bi-commissural calcifications are usually considered major contraindications for PMC, as well as the evidence of left atrial thrombosis, more than mild mitral regurgitation, or concomitant diseases requiring surgery.
Centres which are experienced in mitral valve disease treatment, with a high volume of surgical and percutaneous mitral repair, can achieve good results also in non-optimal candidates, as demonstrated by Dreyfus et al. [8] in a series of 464 patients with unfavourable commissural anatomy. These excellent results, compared to others previously reported for patients unfavourable to PMC [9] , can be obtained only with a scrupulous patient selection, an excellent technical performance, and a perfectly integrated cardiac imaging acquisition during the preoperative and the intraoperative phases. The use of three-dimensional echocardiography and computed tomo graphy imaging for preoperative screening plays a fundamental role in optimising patient selection, and allows extremely accurate evaluation of valve pathology [10] .
The MVA is frequently used as the first cut-off in MS management due to the strict correlation between MVA and clinical presentation.
In standard practice, a value of MVA lower than 1.5 cm 2 is routinely used by operators as a cut-off for PMC indication. Nevertheless, many authors reported good results of valvuloplasty also for moderate or even mild mitral stenosis (MVA > 1.5 cm 2 ) with increased pulmonary pressure or other signs of initial decompensation [11, 12] . In fact, it is common to observe MS-related symptoms even in patients with a MVA greater than 1.5 cm 2 . Dealing with this class of patients, especially when they are young and have a long life expectancy, is always challenging. In many cases, also with suboptimal anatomy, PMC could be a good option to delay surgery or at least to diminish symptoms, but only if the decision-making process is held in a high-volume centre with excellent expertise in the mitral valve disease treatment. Young patients with severe MS can benefit from this approach permitting postponement of mitral valve replacement, avoiding a longer anticoagulation regimen in the case of mechanical prosthesis implantation or early deterioration in the case of bioprosthesis.
Tyczyński et al. [13] retrospectively analysed 1794 consecutive patients treated with PMC for symptomatic MS at the Institute of Cardiology in Warsaw since 1988. The results of this study confirmed the efficacy and the safety of the procedure. Moreover, they demonstrated that even the subgroup of patients with preoperative MVA > 1.5 cm 2 experienced a significant reduction of the left atrial pressure and an increase of the valve area -two of the most important predictors of good long-term outcomes [14] . As underlined by the authors, going beyond classical indications requires not only demonstration of feasibility but also remarking on the potential periprocedural risks, mainly represented by the possibility of significant post-procedural increase of mitral regurgitation. The failure rate did not significantly differ between the two groups and remained comparable to the values published in literature, permitting new perspectives for PMC indications in the future, if larger randomised studies with longer follow-up confirm these results.
The expansion of PMC indications in the near future should deal with the promising perspectives of new transcatheter mitral valve implantations (TMVI), especially in severe mitral annulus calcification [15] . The available data are still limited and TMVI is often used as a last option for very high-risk patients, bringing 30-day mortality in mitral annulus calcification up to 20%. However, the arrival of new devices in the clinical arena and the increased skill of the operators will probably revolutionise the scenario.
Taking into consideration the worldwide clinical needs, especially in developing countries, the need for a cheap, easily reproducible, percutaneous treatment for MS seems clear. In this scenario, PMC could remain a good option also in the future. The technique is still mainly based on the 30-year-old Inoue balloon, giving a chance for technological improvements in the near future.
However, the management of early or late failure of PMC linked to post-procedural mitral insufficiency or progressive restenosis remains an open issue.
In the next few years, high-volume valve centres should improve their multidisciplinary team organisation, trying to offer a real patient-oriented approach in order to propose the best solution for mitral disease based not only on valve anatomy but also on the patient's characteristics, life expectancy, and future technologies.
